Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878461 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Maruho North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT01878461 is a Phase 3 study of Psoriasis that has completed, run by Maruho North America. The registered enrollment target is 542 participants, above the 484-participant average among 125 other Psoriasis trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT01878461, a Phase 3 study of Psoriasis, has completed, sponsored by Maruho North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG M518101
Study Locations (20)
California
- T Joseph Raoof - Encino
- Medical Center for Clinical Research - San Diego
- Therapeutics Clinical Research - San Diego
- Clinical Science Institute - Santa Monica
Florida
- The Center for Clinical and Cosmetic Research - Aventura
- Jacksonville Center for Clinical Research - Jacksonville
Kentucky
- Derm Research - Louiville
- Dermatology Specialists Research - Lousville
Nevada
- Karl G Heine Dermatology - Henderson
- Las Vegas Skin and Cancer Center - Las Vegas
Arizona
- Agave Clinical Research - Mesa
Colorado
- Horizons Clinical Research Center - Denver
Illinois
- Northshore University Health System - Skokie
Indiana
- South Bend Clinic - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01878461
The ClinicalTrials.gov registry entry for NCT01878461 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 542 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 484-participant average among 125 other Psoriasis trials with a reported enrollment target (12% higher). The listed sponsor is Maruho North America, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT01878461 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01878461 about?
NCT01878461 is a clinical study titled "Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis". This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
What is the current status of trial NCT01878461?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 542 participants. The study started on 2013-06. Estimated completion is 2015-05.
What conditions does trial NCT01878461 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01878461?
The interventions under investigation include: Vehicle (DRUG), M518101 (DRUG).
Who is sponsoring clinical trial NCT01878461?
This trial is sponsored by Maruho North America, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01878461 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.